Durlobactam sodium + sulbactam sodium is under clinical development by Entasis Therapeutics and currently in Phase III for Bacteremia. According to GlobalData, Phase III drugs for Bacteremia have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Durlobactam sodium + sulbactam sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Durlobactam sodium + sulbactam sodium overview
Durlobactam sodium and Sulbactam sodium (Xacduro) is a co-packaged kit, acts as an anti bacterial agent. It is formulated as powder for solution for intravenous route of administration. Xacduro is indicated in patients 18 years of age and older for the treatment of hospitalacquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
A fixed-dose combination of durlobactam sodium (ETX2514) and sulbactam is under development for the treatment of urinary tract infections, including acute pyelonephritis, hospital acquired bacterial pneumonia/ventilator acquired bacterial pnuemonia, multi drug-resistant Acinetobacter baumannii infections and Burkholderia pseudomallei infections (Melioidosis). It is administered through intravenous route as a powder for solution. The drug candidate acts by targeting beta-lactamase. ETX-2514 has the activity against classes A, C and D beta-lactamases.
Entasis Therapeutics overview
Entasis Therapeutics (Entasis) is a drug development company. It discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0462 and Zoliflodacin. Its ETX2514 product is a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections. The company’s pipeline products are used to treat multidrug-resistant gram-negative infections such as pseudomonas aeruginosa, acinetobacter baumanii, carbapenem-resistant enterobacteriaceae, and neisseria gonorrhoeae, among others. It also develops robust clinical and pre-clinical pipeline of medicines. Entasis is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Durlobactam sodium + sulbactam sodium’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
